<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01562925</url>
  </required_header>
  <id_info>
    <org_study_id>RenPro-WINE</org_study_id>
    <nct_id>NCT01562925</nct_id>
  </id_info>
  <brief_title>Effect of Red Wine, White Wine and Beer on Contrast-Medium Induced Acute Kidney Injury</brief_title>
  <acronym>RenPro-II-WINE</acronym>
  <official_title>Randomized Controlled Study for Evaluation of the Impact of Red Wine, White Wine and Beer Intake on Contrast-Medium Induced Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with impaired renal function are at elevated risk for development of contrast-medium
      induced acute kidney injury (CI-AKI). CI-AKI is associated with increased risk for
      cardiovascular morbidity and mortality. Effective CI-AKI prevention strategies are needed.

      The RenPro-II-WINE Trial was designed to test the hypothesis whether moderate red wine
      consumption prior to contrast-medium use is effective in CI-AKI prevention.

      Consecutive patients with impaired renal function undergoing elective coronary angiography
      will be assigned in one of four treatment arms: a. control patients receiving standard care
      b. patients receiving standard care plus red wine c. patients receiving standard care plus
      white wine d. patients receiving standard care plus beer This study will give important
      answers on how to prevent CI-AKI in patients with impaired renal function undergoing contrast
      media exposure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CI-AKI incidence</measure>
    <time_frame>&lt;48 hours after contrast-medium exposure</time_frame>
    <description>Increment of serum-creatinin of 0.5 mg/dl or of at least 25% in 48 hours after contrast medium intake from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers assessing acute kidney injury</measure>
    <time_frame>&lt;48 hours</time_frame>
    <description>Changes of urinary neutrophil gelatinase-associated lipocalin (NGAL), serum creatinin and cystatine after coronary angiogram.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Chronic Renal Failure/ Kidney Disease</condition>
  <condition>Contrast-medium Induced Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Red Wine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to red wine group will receive standard care plus two doses of red wine: the evening before contrast-medium use and the morning of contrast-medium exposure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>White wine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Beer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients assigned to control group will receive standard care. Patients receive ordinary still water without alcohol the evening before(7.8 ml per kg bodyweight) and 60-120 minutes before contrast exposure (at least 3.9 ml per kg bodyweight)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Red wine</intervention_name>
    <description>Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure</description>
    <arm_group_label>Red Wine</arm_group_label>
    <other_name>Frühburgunder 2006, Spätlese Trocken, Schloss Westerhaus, Rheinhessen, 12.5% vol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>White wine</intervention_name>
    <description>White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure</description>
    <arm_group_label>White wine</arm_group_label>
    <other_name>Riesling feinherb 2009, Dr. Willkomm, Bernkastel-Kues, 12.5% vol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Beer</intervention_name>
    <description>Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure</description>
    <arm_group_label>Beer</arm_group_label>
    <other_name>Cologne mild beer (Kölsch)</other_name>
    <other_name>Gaffel Kölsch, Gaffel Brauerei Cologne, 4.8% vol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;= 18 years

          -  impaired renal function (baseline estimated glomerular filtration rate of &lt;60 ml/min)

          -  at least three of following comorbidities: hypertension, diabetes mellitus without
             insulin therapy, heart failure NYHA III and/or left ventricular ejection fraction
             &lt;35%, peripheral artery disease, coronary artery disease

        Exclusion Criteria:

          -  known alcohol addiction

          -  severe renal impairment (estimated glomerular filtration rate &lt;15 ml/min and/or in
             chronic dialysis program

          -  Recent (&lt;=30 days) contrast media exposure

          -  insulin therapy

          -  Patients enrolled in concomitant studies

          -  fertile women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Herzzentrum der Universität zu Köln</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2012</study_first_submitted>
  <study_first_submitted_qc>March 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2012</study_first_posted>
  <last_update_submitted>July 4, 2013</last_update_submitted>
  <last_update_submitted_qc>July 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Dr. Fikret Er</investigator_full_name>
    <investigator_title>MD, Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

